SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its President and Chief Executive Officer, Zachary Hornby, will present at the Stifel 2023 Virtual Targeted Oncology Days event which will take place virtually. Presentation details are as follows: Date: Tuesday, … [Read more…]

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® (deutetrabenazine) tablets The U.S. Food and Drug Administration (FDA) approved once-daily AUSTEDO XR extended-release tablets on February 17, 2023 AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia and chorea associated with Huntington’s disease … [Read more…]

Real-world analysis from the REVOLUTIONIZE I study showed hyperkalemia was recurrent following dietary counselling WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will showcase five real-world evidence (RWE) studies from its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio, reinforcing its commitment to advancing science in chronic kidney disease (CKD) and hyperkalemia (HK), at the National Kidney Foundation (NKF) Spring Clinical … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors unanimously rejected the unsolicited proposal it received from Echo Lake Capital to acquire Quince for $1.60 per share in cash. Following careful review and … [Read more…]

The partnership addresses a major gap in providing resources for patients with vision impairment or blindness, including a new focus on mental health care delivery RALEIGH, N.C. & OKLAHOMA CITY & CHICAGO–(BUSINESS WIRE)–Lumata Health, a technology-driven healthcare startup on a mission to prevent vision loss from chronic eye diseases through its human-led, intelligent eye care … [Read more…]

TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formulation Further to Antibe’s update of February 15, 2023, the Company has now selected a clinical … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Oral Solid Dosage Manufacturing Market – Distribution by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current market landscape and future … [Read more…]

WIXOM, Mich.–(BUSINESS WIRE)–$RMTI #EndStageKidneyDisease–Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that the Company is exhibiting its hemodialysis concentrates portfolio in Booth #503 at the National Kidney Foundation Spring Clinical Meetings, which will be held April 11-15, … [Read more…]

RENO, Nev.–(BUSINESS WIRE)–#blockchain–Crucial Data Solutions (CDS), a provider of innovative technologies to advance clinical research, announced today that industry veteran Jim Bob Ward has joined the company as Chief Strategy Officer. In this newly created role, Ward will continue to refine and execute on CDS’ strategic vision for its eClinical platform, TrialKit, by applying his … [Read more…]

DSMC finds no safety concerns, allows use of highest dose for continued administration. Interim analysis of the trial expected in next month Company opens Spanish subsidiary to lead EU clinical trials ATLANTA–(BUSINESS WIRE)–Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with … [Read more…]